Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Minority Interest: 2019-2024

Historic Minority Interest for BridgeBio Pharma (BBIO) over the last 6 years, with Dec 2024 value amounting to $10.2 million.

  • BridgeBio Pharma's Minority Interest fell 5.21% to $10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year decrease of 5.21%. This contributed to the annual value of $10.2 million for FY2024, which is 9.73% down from last year.
  • Per BridgeBio Pharma's latest filing, its Minority Interest stood at $10.2 million for FY2024, which was down 9.73% from $11.2 million recorded in FY2023.
  • In the past 5 years, BridgeBio Pharma's Minority Interest ranged from a high of $48.4 million in FY2020 and a low of $3.4 million during FY2021.
  • For the 3-year period, BridgeBio Pharma's Minority Interest averaged around $10.9 million, with its median value being $11.2 million (2023).
  • In the last 5 years, BridgeBio Pharma's Minority Interest surged by 2,055.60% in 2020 and then plummeted by 92.94% in 2021.
  • Yearly analysis of 5 years shows BridgeBio Pharma's Minority Interest stood at $48.4 million in 2020, then plummeted by 92.94% to $3.4 million in 2021, then skyrocketed by 230.66% to $11.3 million in 2022, then dropped by 0.34% to $11.2 million in 2023, then declined by 9.73% to $10.2 million in 2024.